A Screening Study for the ACH471-100 Treatment Study in Patients with Untreated Paroxysmal Nocturnal Hemoglobinuria

Trial Profile

A Screening Study for the ACH471-100 Treatment Study in Patients with Untreated Paroxysmal Nocturnal Hemoglobinuria

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs ACH 4471 (Primary)
  • Indications Paroxysmal nocturnal haemoglobinuria
  • Focus Therapeutic Use
  • Sponsors Achillion Pharmaceuticals
  • Most Recent Events

    • 07 Jul 2017 Status changed from recruiting to completed.
    • 23 Feb 2017 Status changed from not yet recruiting to recruiting.
    • 11 Jan 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top